<DOC>
	<DOCNO>NCT02199379</DOCNO>
	<brief_summary>The purpose multicenter , open-label , non-randomized , single , oral dose , sequential-cohort study determine pharmacokinetics safety lenvatinib ( 24 mg ) administer healthy subject subject renal impairment .</brief_summary>
	<brief_title>A Phase 1 , Open-Label , Single-Dose , Pharmacokinetic Safety Study E7080 ( 24 mg ) Administered Subjects With Mild , Moderate , Severe Renal Impairment Healthy Subjects</brief_title>
	<detailed_description>This multicenter , open-label , non-randomized , single-dose , sequential-cohort trial subject renal impairment healthy subject . The study consist two phase : A Pretreatment Phase Treatment Phase . The two period Pretreatment Phase : ( 1 ) Screening Period ( last 29 day ) , ( 2 ) Baseline Period ( one day ) . The Treatment Period Treatment Phase last 8 day . The study enroll sufficient number subject 24 26 subject complete study . This include six subject mild renal impairment ( Group 1 ) , six subject moderate renal impairment ( Group 2 ) , four six subject severe renal impairment ( Group 3 ) eight subject normal renal function ( Group 4 ) . Subjects determine eligible protocol receive single 24-mg oral dose E7080 Day 1 . Subjects discharge clinical site Day 8 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion Criteria All subject meet follow criterion include study : 1 . Male female subject , age 18 79 , inclusive , time informed consent 2 . BMI , 18 40 kg/m2 , inclusive , Screening 3 . Nonsmokers smoker smoke 10 cigarette per day 4 . All female must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit betahuman chorionic gonadotropin [ BhCG ] Screening Visit within 72 hour first dose study drug ) . Females childbearing potential , practice total abstinence vasectomise partner confirm azoospermia , must agree use two highly effective method contraception : e.g. , 1 ) intrauterine device ( IUD ) intrauterine system ( IUS ) ; 2 ) barrier method condom occlusive cup ( diaphragm cervical/vault cap ) plus spermicide ( foam , gel , cream , etc . ) ; 3 ) oral , inject , implanted hormonal contraceptive throughout entire study period 30 day study drug discontinuation . Use doublebarrier method ( i.e. , use time condom plus occlusive cup [ diaphragm cervical/vault cap ] plus spermicide [ foam , gel , cream , etc . ] ) accept two highly effective method contraception . The subject exempt requirement postmenopausal woman ( defined woman amenorrheic least 12 consecutive month , appropriate age group , without know suspected primary cause ) subject sterilize surgically otherwise prove sterile ( i.e. , bilateral tubal ligation surgery least 1 month prior dose , total hysterectomy , bilateral oophorectomy surgery least 1 month prior dose ) . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 5 . Male subject partner woman childbearing potential must use condom plus spermicide female partner childbearing potential must use highly effective method contraception ( see method describe Inclusion Criterion No . 4 ) begin least one menstrual cycle prior start study drug , throughout entire study period , 30 day last dose study drug , unless male subject totally sexually abstinent undergone successful vasectomy confirm azoospermia unless female partner sterilize surgically otherwise prove sterile ( see Inclusion Criterion No.4 ) . 6 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol . For healthy subject normal renal function follow key inclusion criterion also apply : 1 . Creatinine clearance great equal 90 mL/min . For subject renal impairment , follow key inclusion criterion also apply : 1 . Subjects must diagnosis renal impairment stable , without change disease status , 60 day prior study screen , determine investigator . 2 . Mild ( creatinine clearance , 6089 mL/min ) , moderate ( creatinine clearance , 3059 mL/min ) , severe ( creatinine clearance , 1529 mL/min ) renal impairment 3 . Other renal impairment , subject must history clinically relevant disease condition ( e.g. , significant cardiac hepatic dysfunction , diseases gastrointestinal tract condition may impact drug absorption ) , determine investigator . 4 . Subjects history Type I Type II diabetes permissible , provide , opinion investigator , stable disease . Subjects receive insulin therapy permissible provide stable treatment least 2 week prior study enrollment continue study . 5 . QT interval correct heart rate ( QTc ) calculate Fridericia 's formula ( QTcF ) interval less equal 500 msec Screening Baseline . 6 . Subjects may enrol joint approval principal investigator ( PI ) medical monitor base subject history stability renal impairment . Exclusion Criteria Subjects meet follow criterion exclude study : All Subjects : 1 . Use new medication , include multivitamin , investigational drug within 14 day prior drug administration , within five time elimination halflife , whichever long , except combine oral contraceptive occasional use paracetamol ibuprofen within 14 day local anesthetic within 3 day study drug administration . Current overthecounter ( OTC ) drug prescription medication use permit , must stable consistent least 14 day prior Screening throughout study treatment period . 2 . Positive HIV screen test 3 . Presence acute , active liver disease acute liver injury indicate ( 1 ) abnormal liver function test , ( 2 ) clinical laboratory sign acute , active hepatitis A , B , C 4 . Systolic blood pressure great equal 160 mm Hg and/or diastolic blood pressure great equal 100 mm Hg healthy subject subject mild renal impairment ; systolic blood pressure great equal 180 mm Hg and/or diastolic blood pressure great equal 110 mm Hg subject moderate severe renal impairment . Readings confirm repeat determination one hour first measurement . Healthy Subjects : In addition Key Exclusion Criteria subject , standard exclusion criterion healthy subject Phase 1 study use . These include : 1 . Subjects clinically significant illness require medical treatment within 8 week clinically significant infection within 4 week dose 2 . Subjects history myocardial infarction active ischemic heart disease 3 . Subjects disease may influence outcome study , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism within 4 week prior dose 4 . Gastrointestinal malabsorption condition may affect PK profile E7080 include history gastrointestinal surgery ( hepatectomy , digestive organ resection , etc . ) ( Appendectomy cholecystectomy , however , permit . ) 5 . Subjects history clinically significant drug food allergy presently experience significant seasonal allergy 6 . Subjects experience weight loss gain great 10 % Screening prior dose 7 . Subjects QTc interval great 450 msec demonstrate repeat electrocardiogram ( ECG ) Screening 8 . Subjects hemoglobin level le 12.0 g/dL 9 . Significant finding reveal history , physical clinical laboratory test 10 . Subjects know suspected history drug alcohol misuse within 6 month prior Screening , positive urine drug alcohol test Screening Baseline 11 . Subjects consume caffeinated beverage food within 72 hour prior dose 12 . Receipt another investigational drug device within 4 week prior dose five halflives investigational drug , whichever longer 13 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within one week dose 14 . Subjects engage heavy exercise within 2 week prior checkin ( e.g. , marathon runner , weight lifter , etc . ) 15 . Subjects unwilling abide requirement study , opinion investigator , likely complete study . Subjects Renal Impairment : 1 . A history renal transplant 2 . Known significant bleeding diathesis ( e.g. , history recent bleeding esophageal varix ) , could preclude multiple venipuncture deep intramuscular injection 3 . Significant acute , new onset illness within 2 week prior study drug administration . In addition Key Exclusion Criteria All Subjects Subjects Renal Impairment , standard exclusion criterion healthy subject Phase 1 study use subject renal impairment . These include : 4 . Subjects clinically significant illness , say illness unrelated renal impairment , require medical treatment within 8 week clinically significant infection within 4 week dose 5 . Subjects history significant cardiovascular impairment : history congestive heart failure great New York Heart Association ( NYHA ) Class II ; unstable angina ; myocardial infarction stroke within 6 month first dose study drug ; cardiac arrhythmia require medical treatment 6 . Subjects disease may influence outcome study , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , subject congenital abnormality metabolism within 4 week prior dose 7 . Gastrointestinal malabsorption condition may affect PK profile E7080 include history gastrointestinal surgery ( hepatectomy , digestive organ resection , etc. ) . ( Appendectomy cholecystectomy , however , permit . ) 8 . Subjects know history clinically significant drug food allergy presently experience significant seasonal allergy 9 . Subjects experience weight loss gain great 10 % Screening prior dose 10 . Significant finding reveal history , physical clinical laboratory test say finding unrelated subject 's renal impairment 11 . Subjects know suspected history drug alcohol misuse within 6 month prior Screening , positive urine drug alcohol test Screening Baseline 12 . Subjects consume caffeinated beverage food within 72 hour prior dose 13 . Receipt another investigational drug device within 4 week prior dose five halflives investigational drug , whichever longer 14 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within one week dose 15 . Subjects engage heavy exercise within 2 week prior checkin ( e.g. , marathon runner , weight lifter , etc . ) 16 . Subjects unwilling abide requirement study , opinion investigator , likely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>disease severity</keyword>
</DOC>